Xenon Pharmaceuticals Inc.
XENE
Rank in Stocks
#4407
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Share Price
$36.50
Market Cap
$3.53B
Change (1 day)
4.06%
Change (1 year)
-15.97%
Country
CA
Trade Xenon Pharmaceuticals Inc. (XENE)
Category
Healthcare
Revenue for Xenon Pharmaceuticals Inc. (XENE)
Revenue in Jun 2026 TTM: 0.00
According to Xenon Pharmaceuticals Inc. latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 a decrease compared to the revenue in the year 2022 that was $9.43M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Xenon Pharmaceuticals Inc. from 2011 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $9.43M | -48.83% |
| 2021 | $18.44M | -42.68% |
| 2020 | $32.17M | 371.02% |
| 2019 | $6.83M | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $311.00K | -82.75% |
| 2016 | $1.80M | -88.43% |
| 2015 | $15.58M | -45.09% |
| 2014 | $28.37M | 3.71% |
| 2013 | $27.36M | 91.19% |
| 2012 | $14.31M | 106.82% |
| 2011 | $6.92M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
